# Essential Hypertension

A practical approach to confirm sustained hypertension with out-of-office measurement, stratify treatment thresholds by cardiovascular risk, avoid white-coat misclassification, and systematically distinguish apparent from true resistant hypertension before intensifying therapy.

**Clinical question:** How should clinicians confirm, treat, and monitor essential hypertension while identifying white-coat, masked, and resistant phenotypes?

Updated: 2026-08-24T16:23:09.905291+00:00

## What matters in practice
- Under ACC/AHA criteria, hypertension begins at office BP 130/80 mm Hg; BP 140/90 mm Hg is stage 2 hypertension. [2][14][16]
- For untreated office SBP 130-159 mm Hg or DBP 80-99 mm Hg, confirm or exclude white-coat hypertension with daytime ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) before labeling sustained hypertension. [9]
- Use out-of-office BP to distinguish white-coat from masked hypertension; ABPM has stronger cardiovascular outcome-prediction data, and agreement between HBPM and ABPM for white-coat classification is only 60%-70%. [8][9]
- Initiate antihypertensive medication for established cardiovascular disease or estimated 10-year ASCVD risk greater than 10% when BP is at least 130/80 mm Hg; treat BP at least 140/90 mm Hg regardless of calculated risk. [14]
- Do not diagnose true resistant hypertension until adherence, measurement quality, and white-coat effect have been addressed and the patient is receiving maximally tolerated three-drug therapy including an ACE inhibitor or ARB, long-acting dihydropyridine calcium-channel blocker, and diuretic. [22][23]

## Confirm sustained hypertension before committing to long-term treatment

Office BP is a screening measurement; management depends on whether elevation persists outside the clinical setting.

Use the ACC/AHA office classification at the decision point: stage 1 hypertension is SBP 130-139 mm Hg or DBP 80-89 mm Hg, and stage 2 hypertension is BP at least 140/90 mm Hg. This lower diagnostic threshold differs from European guidance, which retains 140/90 mm Hg for diagnosis. [2][14][16]

In an untreated adult with office SBP greater than 130 but less than 160 mm Hg or DBP greater than 80 but less than 100 mm Hg, obtain daytime ABPM or HBPM to screen for white-coat hypertension before diagnosing hypertension. This is particularly consequential when drug treatment would otherwise be deferred or initiated solely from office readings. [9]

Classify discordant measurements explicitly. White-coat hypertension is elevated office BP with lower ambulatory or home BP; masked hypertension is the inverse pattern. Do not regard HBPM and ABPM as interchangeable when a decision to withhold or avoid intensifying medication hinges on the result: their diagnostic overlap for white-coat hypertension is only 60%-70%, and ABPM has stronger cardiovascular risk-prediction evidence. [8][9]
- Choose ABPM when nocturnal BP, a white-coat decision with high clinical consequences, or a resistant-hypertension evaluation is at issue. [9][23]
- Use HBPM when ABPM is unavailable or impractical; it remains guideline-supported for diagnosis and longitudinal treatment monitoring. [8][9]
- Consider masked hypertension when office BP appears controlled but clinical context suggests uncontrolled out-of-office BP; ABPM or HBPM changes classification and prevents false reassurance. [5][8][9]

*Out-of-office BP phenotypes direct whether to defer, initiate, or intensify therapy. [8][9]*

| Office BP | Out-of-office BP | Phenotype | Clinical next step |
| --- | --- | --- | --- |
| Elevated | Elevated | Sustained hypertension | Risk-stratify and initiate or intensify lifestyle and drug treatment according to BP level and cardiovascular risk. [14] |
| Elevated | Lower | White-coat hypertension | Avoid treatment escalation based on office BP alone; follow periodically with ABPM or HBPM for progression to sustained hypertension. [9][12] |
| Lower | Elevated | Masked hypertension | Treat as an uncontrolled out-of-office BP phenotype; confirm with ABPM or HBPM rather than accepting office control. [5][8][9] |
| Lower | Lower | Controlled or normotensive phenotype | Continue risk-based surveillance and use out-of-office readings to monitor treated patients. [8][9] |

## Establish cardiovascular risk and identify findings that change management

After sustained elevation is established, determine whether the BP level and cardiovascular risk support medication now.

Obtain HbA1c, electrolytes, creatinine with estimated glomerular filtration rate, total cholesterol, and HDL cholesterol; examine the fundi for hypertensive retinopathy; and obtain a 12-lead ECG. These tests identify kidney dysfunction, diabetes, lipid risk, retinal target-organ injury, and cardiac abnormalities that alter global cardiovascular-risk assessment and treatment planning. [21]

For adults with established cardiovascular disease, begin antihypertensive pharmacotherapy at BP at least 130/80 mm Hg. The same medication threshold applies to patients with an estimated 10-year ASCVD risk greater than 10%; patients with SBP at least 140 mm Hg or DBP at least 90 mm Hg should receive drug treatment regardless of calculated cardiovascular risk. [14]

Use the 130/80 mm Hg ACC/AHA threshold as the U.S. framework, but recognize that classification and treatment thresholds are not internationally uniform. European guidance uses a diagnostic threshold above 140/90 mm Hg, while both guideline approaches endorse drug treatment for established cardiovascular disease at BP at least 130/80 mm Hg and for BP at least 140/90 mm Hg independent of calculated risk. [14]
- At BP 130-139/80-89 mm Hg without established cardiovascular disease, calculate 10-year cardiovascular risk before deciding whether lifestyle therapy alone is sufficient or medication should be added. [14]
- At BP at least 140/90 mm Hg, do not defer pharmacotherapy solely because calculated 10-year risk is low. [14]
- Continue lifestyle counseling whether medications are started, declined, or deferred; guidelines recommend ongoing lifestyle advice for suspected and confirmed hypertension. [3][20][21]

*Risk-based medication thresholds in the ACC/AHA framework. [14]*

| Clinical branch | BP threshold | Medication decision |
| --- | --- | --- |
| Established cardiovascular disease | At least 130/80 mm Hg | Start antihypertensive medication with lifestyle intervention. [14] |
| Estimated 10-year ASCVD risk greater than 10% | At least 130/80 mm Hg | Start antihypertensive medication with lifestyle intervention. [14] |
| No established cardiovascular disease and lower calculated risk | 130-139/80-89 mm Hg | Use lifestyle intervention and reassess BP/risk rather than automatically starting medication. [3][14] |
| Any cardiovascular-risk category | At least 140/90 mm Hg | Start antihypertensive medication. [14] |

## Treat to an out-of-office-informed BP goal and monitor the actual response

A treatment plan should address both cardiovascular risk and the possibility that office readings misrepresent usual BP.

For most adults in the ACC/AHA framework, the treatment target is BP below 130/80 mm Hg. The rationale for lower targets includes trial evidence that intensive BP lowering reduces cardiovascular risk, although treatment intensity must be individualized when adverse effects, comorbidity, or measurement uncertainty make further escalation unsafe or uninformative. [1][15]

Use HBPM or ABPM to assess response after treatment changes rather than relying exclusively on office BP. Out-of-office monitoring both improves recognition of uncontrolled BP and identifies white-coat uncontrolled hypertension, in which medication escalation based on office BP alone can expose patients to unnecessary chronic treatment. [5][7][9][12]

Maintain lifestyle intervention throughout treatment. Recommended targets include dietary improvement, regular exercise, reduction of excessive alcohol intake, weight reduction when indicated, smoking cessation, and avoidance of over-the-counter or other agents that may contribute to poor BP control. [20][21][23]
- If office BP remains above goal but HBPM or ABPM is controlled, evaluate for a white-coat effect before increasing medication. [5][9][22]
- If office BP is controlled but HBPM or ABPM is elevated, identify masked uncontrolled hypertension and intensify management according to the out-of-office phenotype. [5][8][9]
- In confirmed white-coat hypertension, use periodic ABPM or HBPM rather than routine drug initiation solely for elevated office BP; annual or semiannual reassessment has been advised to detect conversion to sustained hypertension. [9][12]

*Monitoring decisions after an office BP result. [5][8][9][12]*

| Observed pattern | Test to obtain or review | Interpretation | Action |
| --- | --- | --- | --- |
| Untreated office BP 130-159/80-99 mm Hg | Daytime ABPM or HBPM | Determines whether elevation is sustained or white-coat. [9] | Base diagnosis and treatment threshold on the confirmed phenotype. [9][14] |
| Treated office BP above goal | ABPM or HBPM | Distinguishes sustained uncontrolled BP from white-coat uncontrolled BP. [5][9] | Do not intensify until out-of-office control is known when feasible. [9][22] |
| Treated office BP at goal with high-risk clinical concern | ABPM or HBPM | Can reveal masked uncontrolled hypertension. [5][8] | Treat the confirmed out-of-office elevation rather than accepting office control. [5][9] |

## Separate pseudo-resistance from true resistant hypertension

Resistant hypertension is a confirmation diagnosis, not a label for any patient with an elevated office BP on several drugs.

Define apparent resistant hypertension as BP above goal despite at least three antihypertensive agents of different mechanisms at maximally tolerated doses, preferably including an ACE inhibitor or ARB, a long-acting dihydropyridine calcium-channel blocker, and a diuretic; controlled BP requiring at least four medications also meets the resistant-hypertension definition. [22] Before assigning true resistance, exclude poor measurement technique, nonadherence, and white-coat effect. [22][23][24]

Confirm persistent out-of-office elevation with ABPM or HBPM after adherence and lifestyle factors have been assessed. In an apparent-resistant cohort evaluated with office and ambulatory readings, 9% had white-coat uncontrolled hypertension and 15% had masked uncontrolled hypertension, illustrating why office BP alone should not trigger serial drug escalation. [5]

Evaluate confirmed resistant hypertension for secondary causes after pseudo-resistance is removed. The practical sequence is to verify the prescribed regimen and maximal tolerated doses, assess adherence, review sodium intake and precipitating medications or acute conditions, confirm out-of-office BP, then pursue a directed secondary-hypertension evaluation. [22][23][24]
- Review whether the core three-drug regimen contains an ACE inhibitor or ARB, a long-acting dihydropyridine calcium-channel blocker, and a diuretic before labeling treatment failure. [22]
- Assess adherence directly; nonadherence is a major pseudo-resistance mechanism and may reflect intermittent dosing, dose reduction, or fear of hypotension. [22][24]
- Review sodium exposure, smoking, exercise, weight, and over-the-counter medications before adding agents. [23][24]
- Evaluate for secondary hypertension once true resistance is confirmed because resistant hypertension warrants such an evaluation. [22]

### Pharmacologic intensification

For resistant hypertension on optimized baseline therapy, add low-dose spironolactone when potassium is 4.5 mmol/L or lower, with particular caution in reduced eGFR because of hyperkalemia risk. Check sodium, potassium, and renal function within 1 month of starting additional diuretic therapy and repeat as clinically indicated. [21]

If further therapy is needed after the mineralocorticoid receptor antagonist step, vasodilating beta-blockers such as labetalol, carvedilol, nebivolol, or bisoprolol are potential next-line choices; clonidine is another option, and a transdermal formulation can reduce frequent oral dosing and lower rebound-hypertension risk. Agent selection should be individualized to comorbidity and tolerability. [22]
- Do not add spironolactone without baseline potassium and kidney-function assessment. [21]
- Repeat sodium, potassium, and renal function within 1 month after adding further diuretic therapy. [21]
- Use ABPM or HBPM after each major treatment decision to ensure that apparent treatment failure is not a white-coat phenotype. [5][9][23]

*Stepwise approach to apparent resistant hypertension. [5][21][22][23][24]*

| Step | Required assessment | Interpretation | Next action |
| --- | --- | --- | --- |
| 1. Verify the regimen | Confirm maximally tolerated three-drug therapy, preferably ACE inhibitor/ARB plus long-acting dihydropyridine calcium-channel blocker plus diuretic. [22] | An incomplete regimen is not true resistant hypertension. [22] | Optimize the foundational regimen before adding further agents. [22] |
| 2. Exclude pseudo-resistance | Assess BP technique, adherence, sodium intake, precipitating conditions, and medications. [22][23][24] | Any correctable contributor can explain apparent resistance. [22][24] | Correct the contributor and reassess BP. [22][23] |
| 3. Confirm out-of-office BP | Obtain ABPM or HBPM. [5][23] | Normal out-of-office BP indicates white-coat uncontrolled hypertension rather than sustained resistance. [5][22] | Avoid reflex escalation for white-coat effect; monitor longitudinally. [5][9] |
| 4. Intensify true resistance | Check potassium and eGFR; consider low-dose spironolactone if potassium is 4.5 mmol/L or lower. [21] | Reduced eGFR increases hyperkalemia risk. [21] | Monitor sodium, potassium, and renal function within 1 month. [21] |
| 5. Investigate secondary causes | Perform evaluation after true resistant hypertension is confirmed. [22] | Secondary disease is more likely in confirmed resistance than in pseudo-resistance. [22] | Pursue cause-directed management while continuing BP control. [22][23] |

## Recognize when hypertension requires urgent evaluation or specialist-level assessment

The urgency of BP reduction depends on target-organ injury, not the numeric value alone.

Severe hypertension with overt target-organ damage is a hypertensive emergency and requires emergency evaluation, intravenous titratable BP reduction, and hospital-level monitoring. Rapid normalization is unsafe in chronic hypertension because autoregulatory adaptation can make abrupt lowering cause tissue hypoperfusion; an incremental reduction strategy is required. [13]

Escalate confirmed resistant hypertension for directed secondary-cause evaluation when BP remains above goal after adherence verification, out-of-office confirmation, and optimized multidrug therapy. Resistant hypertension carries increased risk of cardiovascular disease, stroke, kidney failure, and death, so repeated office-only medication changes are not an adequate endpoint. [22]

Use the initial hypertension evaluation to identify renal impairment, retinopathy, ECG abnormalities, diabetes, and dyslipidemia, then incorporate these findings into the urgency of follow-up and global cardiovascular-risk reduction. [21]
- Send patients with severe hypertension and overt neurologic, ocular, cardiac, or other target-organ injury for emergency evaluation rather than outpatient oral-dose adjustment. [13]
- Use IV rather than oral therapy when titratable BP reduction is necessary for hypertensive emergency management. [13]
- Refer or co-manage confirmed resistant hypertension after pseudo-resistance has been excluded and secondary-cause workup is indicated. [22][23]

*Escalation framework for severe or difficult-to-control BP. [13][22][23]*

| Clinical situation | Key discriminator | Disposition |
| --- | --- | --- |
| Severe BP elevation with overt target-organ damage | Hypertensive emergency; acute end-organ injury determines urgency. [13] | Emergency department evaluation, intravenous titratable treatment, and hospitalization/monitoring. [13] |
| Elevated office BP on three or more agents | Confirm adherence, technique, and ABPM/HBPM before calling it resistant. [22][23] | Address pseudo-resistance before pharmacologic escalation. [22][24] |
| Persistent elevated out-of-office BP despite optimized multidrug therapy | Confirmed resistant hypertension. [22][23] | Evaluate secondary causes and add therapy with potassium/renal monitoring when spironolactone is used. [21][22] |

## References
1. Blood Pressure Lowering and Risk of Mortality in Chronic ... — jamanetwork.com — https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2652833
2. The ACC/AHA 2017 Hypertension Guidelines — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M17-3103
3. Hypertension | Annals of Internal Medicine — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/AITC201905070
4. Synopsis of the 2020 U.S. Department of Veterans Affairs ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M20-3798
5. Out-of-office blood pressure monitoring in defining and confirming true resistant hypertension | Hypertension Research — www.nature.com — https://www.nature.com/articles/s41440-025-02097-z
6. Diagnosis of White Coat Hypertension by Ambulatory Blood Pressure Monitoring — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/01.HYP.34.2.267
7. Predicting Out-of-Office Blood Pressure in the Clinic (PROOF-BP) | Hypertension — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.115.07108?doi=10.1161%2FHYPERTENSIONAHA.115.07108
8. Prognosis of White-Coat and Masked Hypertension | Hypertension — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/hypertensionaha.113.02741
9. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/hyp.0000000000000065
10. White Coat Hypertension - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/white-coat-hypertension
11. Reproducibility of white-coat and masked hypertension in ambulatory BP monitoring - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S016752730600578X
12. White Coat Hypertension - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/white-coat-hypertension
13. Hypertensive Urgency - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/hypertensive-urgency
14. 2023 ESH Hypertension Guideline Update: Bringing Us ... — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2024/02/05/11/43/2023-esh-hypertension-guideline-update
15. New in Clinical Guidance | High Blood Pressure Focus ... — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2025/10/01/01/new-in-clinical-guidance-hbp
16. High blood pressure redefined for first time in 14 years: 130 is the new high - American College of Cardiology — www.acc.org — https://www.acc.org/about-acc/press-releases/2017/11/13/15/35/high-blood-pressure-redefined-for-first-time-in-14-years-130-is-the-new-high
17. Comparing Guideline Recommendations of Statin Use For ... — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2022/10/04/13/38/comparing-guideline-recommendations-of-statin-use-for-the-primary-prevention-of-ascvd
18. 2024 Elevated Blood Pressure and Hypertension — www.escardio.org — https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/elevated-blood-pressure-and-hypertension
19. Screening for Primary Hypertension in Children and ... — pediatrics.aappublications.org — https://pediatrics.aappublications.org/content/132/5/907
20. Hypertension in adults — www.nice.org.uk — https://www.nice.org.uk/guidance/gid-ng10054/documents/draft-guideline
21. Hypertension in adults: diagnosis and management — www.nice.org.uk — https://www.nice.org.uk/guidance/ng136/chapter/Recommendations
22. Resistant hypertension: A stepwise approach | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/content/90/2/115
23. What is new in resistant hypertension? — www.escardio.org — https://www.escardio.org/communities/councils/cardiology-practice/education/cardiopractice/what-is-new-in-resistant-hypertension
24. Combination therapy at the start of hypertension treatment: pros and cons — www.escardio.org — https://www.escardio.org/communities/councils/cardiology-practice/scientific-documents-and-publications/ejournal/volume-17/combination-therapy-at-the-start-of-hypertension-treatment-pros-and-cons

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.